By: Rapid Access International, Inc. August 2020
As we enter the fall, there is much anticipation about a possible resurgence of COVID-19 cases; especially in schools and on college campuses around the United States. College towns are very much in focus, as they bring in students from around the country and increase the risk of the virus’ spread.
Researchers at PolicyLab at Children's Hospital of Philadelphia (CHOP) have warned of increased case counts in Midwestern college towns and large New England cities, such as Boston, Providence, and Hartford.1
New guidelines from CDC, issued on August 24th, reverses a previous recommendation that anyone who came into close contact with people known to be infected should be tested. The CDC now recommends, “If you have been in close contact (within 6 feet) of a person with a COVID-19 infection for at least 15 minutes but do not have symptoms, you do not necessarily need a test unless you are a vulnerable individual or your health care provider or State or local public health officials recommend you take one.”2
This new guidance would seem to fly in the face of the risks associated with the virus’ spread. Indeed, the guidance has come on the heels of a study published by the Journal of Pediatrics that finds that asymptomatic young people could be "silent spreaders" of COVID-19, with higher levels of the virus in their systems than hospitalized adults.3
The reasons for this new guidance are not the focus of this article; however, it is worth noting that the rationale may be political. Brett Giroir, the assistant secretary of health responsible for testing, confirmed on 26 August that the impetus for the change had come from the White House.4
In spite of the new CDC guidelines, universal testing within companies, including Amazon, and on college campuses, has been embraced as a way to mitigate the risk of the virus’ spread. Amazon committed to building diagnostic labs to test their warehouse workers months ago. But, now Abbott has gained FDA approval for a quick and inexpensive test that can be more widely adopted.
On August 26th, Abbott announced that the U.S. Food and Drug Administration (FDA) had issued Emergency Use Authorization (EUA) for its BinaxNOWTM COVID-19 Ag Card rapid test for detection of COVID-19 infection.5 The card is small (about the size of a credit card), costs $5, and results are provided within 15 minutes of the time a sample is taken by a healthcare worker.
According to the press release, “[t]he BinaxNOW COVID-19 Ag Card demonstrated sensitivity of 97.1% (positive percent agreement) and specificity of 98.5% (negative percent agreement) in patients suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset.”6
Other key points from the press release include the following :7
In addition to the BinaxNOW card, Abbott is also offering a mobile app at no charge “that will allow people to display their results obtained through a healthcare provider when entering facilities requiring proof of testing”.8 The app is available in the app stores for both Apple and Android mobile devices.
Robert B. Ford, president and chief executive officer at Abbott Laboratories, explained the relationship between the card and the app: "While BinaxNOW is the hardware that makes knowing your COVID-19 status possible, the NAVICA app is the digital network that allows people to share that information with those who need to know”.9
If test results are negative, the app will display a digital health pass via a QR code, similar to an airline boarding pass. If test results are positive, people receive a message to quarantine and talk to their doctor.
-----------------------------------------------------------------
Copyright © 2009-2021 Mitsubishi Research Institute, Inc.